A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 μg ethinylestradiol and either 2 mg chlormadinone acetate or 150 μg desogestrel

Winkler, Ulrich; Daume, E.; Sudik, R; Oberhoff, C.; Bier, U.; Hallmann, Christoph; Andreas, Jens-Otto; Schindler, A. E.

doi:10.1080/13625189909040809

Cited by 15 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In sample I of our study, protein S levels were lower in users of Marvelon ® (containing third‐generation DSG) than Microgynon ® (containing second‐generation LNG). A number of previous studies have shown that protein S is decreased in women receiving COC pills (Granata et al , 1991; Archer et al , 1999; Winkler et al , 1999). The effect is probably mediated by oestrogen, as high‐dose EE alone in young girls of tall stature resulted in a marked decrease in protein S, which took at least 4 weeks to reverse (Van Ommen et al , 1999).…”

Section: Discussionmentioning

confidence: 94%

Protein S levels are lower in women receiving desogestrel‐containing combined oral contraceptives (COCs) than in women receiving levonorgestrel‐containing COCs at steady state and on cross‐over

Mackie¹,

Piegsa

Furs³

et al. 2001

Br J Haematol

View full text Add to dashboard Cite

Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over Summary. This study aimed to identify specific haemostatic changes that might account for previous observations of higher venous thromboembolic risk among users of combined oral contraceptives (COCs) containing desogestrel (DSG) than levonorgestrel (LNG). Sixty-three current users of monophasic 30 mg oestrogen COCs containing either LNG or DSG omitted one pill-free interval (PFI), switching immediately either to the opposite formulation for one cycle or continuing with the same pill. Venesection followed the initial PFI after one cycle (21 tablets) and two cycles (42 tablets) of continuous pill taking, and after the following PFI. Protein S was lower in users of DSG than LNG formulations after the first PFI (mean^SD, 0´67^0´09 vs 0´76^0´10, P , 0´001) and after one cycle (0´61^0´09 vs 0´76^0´09, P , 0´0001). Protein S decreased when switching from LNG to DSG pills (0´77^0´07±0´65^0´06, P , 0´0001), mirrored by an increase at switching from DSG to LNG formulations (0´61^0´08±0´73^0´10, P , 0´005). Mean protein S levels remained within the normal range. Three different markers of thrombin generation remained unaltered. Potential explanations for COC-related thrombotic events are`acquired resistance to activated protein C' or inhibition of fibrinolysis. A potential role has been described for protein S deficiency in both. A further triggering factor is a probable prerequisite for actual thrombosis, but pill-takers whose levels of protein S were in the lowest percentiles may be at greatest risk.

show abstract

Section: Discussionmentioning

confidence: 94%

Protein S levels are lower in women receiving desogestrel‐containing combined oral contraceptives (COCs) than in women receiving levonorgestrel‐containing COCs at steady state and on cross‐over

Mackie¹,

Piegsa

Furs³

et al. 2001

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…The relative risk of thrombosis during the use of desogestrel, gestodene, drospirenone, and contraceptive intravaginal rings was 4-6 with NNH: 952-1587 [ 39 ]. Chlormadinone acetate was reported to have a similar risk profile to desogestrel [ 40 ].…”

Section: Oral Contraception and The Risk Of Thrombosismentioning

confidence: 99%

Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age

Słopień¹,

Milewska²,

Rynio³

et al. 2018

View full text Add to dashboard Cite

Hormonal contraception in both reproductive and late reproductive age, as well as contraceptive action, is used also for other indications like dysmenorrhoea, menstrual disorders, endometriosis, acne vulgaris, and hirsutism. Acne vulgaris and hirsutism are important signs related to hyperandrogenaemia and present a serious medical problem for the patients and a challenge for medical doctors in terms of effective treatment. The application of hormonal contraception to treat acne vulgaris and hirsutism requires knowledge of the mechanism of antiandrogenic actions and the possible contraindications and complications. These data are presented in this review.

show abstract

“…Elevated cFVIIa plasma levels thus may represent a pronounced prothrombotic blood capacity, which may be of clinical importance in case of atherosclerotic vascular defects, as tissue factor-producing cells have been identified in atherosclerotic plaques. cFVIIa is a potent hemostatic stimulus , as complex formation of FVIIa with tissue factor is the main physiological triggering mechanism of blood coagulation [14, 22]. …”

Section: Discussionmentioning

confidence: 99%

Inhibitory effect of ethinylestradiol on coagulation factors in rats

Franco-Murillo

Jaimez

2017

Exp. Anim.

View full text Add to dashboard Cite

Epidemiological and experimental data have indicated the beneficial and adverse effects of estrogenic replacement therapy. In the present study, we explored the effect of ethinylestradiol (EE) and 17β-estradiol (E 2 ) on screening tests, prothrombin time (PT) and activated partial thromboplastin time (APTT), as well as the activity of coagulation factors (FVII, FX, FXI, and FXII) in male Wistar rats. Animals were injected subcutaneously during three consecutive days with EE or E 2 (1, 3, 10, and 30 mg/kg) and propylene glycol (0.3 ml; vehicle, V). EE produced significant increments (P<0.05) on PT (8, 13, 15, and 10%) and APTT (32, 35, and 28%), whereas E 2 did not show any effect. EE diminished the activity of factors VII (−10, −13, and −10%) and X (−10, −9, −15, and −14%; P<0.05), and E 2 (1 mg/kg) produced a modest increment (8%; P<0.05) on FX only. E 2 (10 mg/kg) showed a diminution of 9% (P<0.05), while EE did not produce any response on factor XII. EE diminished (−15, −14, −19, and −17%) but E 2 augmented (10, 14, 24, and 24%) factor XI activity (P<0.05). Our findings suggest that EE and E 2 produce different effects on coagulation and that EE seems to act across an inhibitory mechanism of coagulation factor activity in the present experimental model.

show abstract

A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 μg ethinylestradiol and either 2 mg chlormadinone acetate or 150 μg desogestrel

Cited by 15 publications

References 15 publications

Protein S levels are lower in women receiving desogestrel‐containing combined oral contraceptives (COCs) than in women receiving levonorgestrel‐containing COCs at steady state and on cross‐over

Protein S levels are lower in women receiving desogestrel‐containing combined oral contraceptives (COCs) than in women receiving levonorgestrel‐containing COCs at steady state and on cross‐over

Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age

Inhibitory effect of ethinylestradiol on coagulation factors in rats

Contact Info

Product

Resources

About